Sterling Investment Advisors (Pennsylvania)’s GSK GSK Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,889	Closed	-$212K	–	265
2022 Q2	$212K	Hold	3,889	–	–	0.07%	132
2022 Q1	$212K	Buy	3,889 +3,689	+1,845%	+$200K	0.06%	140
2021 Q4	$11K	Hold	200	–	–	﹤0.01%	427
2021 Q3	$10K	Hold	200	–	–	﹤0.01%	433
2021 Q2	$10K	Sell	200 -26	-12%	-$1.25K	﹤0.01%	424
2021 Q1	$10K	Hold	226	–	–	﹤0.01%	408
2020 Q4	$10K	Hold	226	–	–	﹤0.01%	370
2020 Q3	$11K	Hold	226	–	–	﹤0.01%	342
2020 Q2	$11K	Buy	226 +200	+769%	+$10.3K	﹤0.01%	337
2020 Q1	$1K	Hold	26	–	–	﹤0.01%	380
2019 Q4	$1K	Hold	26	–	–	﹤0.01%	395
2019 Q3	$1K	Hold	26	–	–	﹤0.01%	407
2019 Q2	$1K	Hold	26	–	–	﹤0.01%	408
2019 Q1	$1K	Buy	+26	New	+$1.3K	﹤0.01%	403
2017 Q4	–	Sell	-19,960	Closed	-$1.01M	–	349
2017 Q3	$1.01M	Sell	19,960 -760	-4%	-$38.6K	0.67%	50
2017 Q2	$1.12M	Hold	20,720	–	–	0.75%	48
2017 Q1	$1.09M	Buy	20,720 +1,716	+9%	+$87.1K	0.79%	43
2016 Q4	$915K	Buy	+19,004	New	+$939K	0.73%	44

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s GSK Position: Q3 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of GSK (GSK) in Q3 2022, closing a stake of 3,889 shares — an estimated $212K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in GSK in Q4 2016 and held it in 18 quarters. The position peaked at $1.12M in Q2 2017. 743 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Sterling Investment Advisors (Pennsylvania) reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Sterling Investment Advisors (Pennsylvania) sold 3,889 GSK shares in Q3 2022, an estimated $212K.
Sterling Investment Advisors (Pennsylvania) first reported a position in GSK in Q4 2016 and held it in 18 quarters.
Sterling Investment Advisors (Pennsylvania)'s GSK position peaked at $1.12M in Q2 2017.
743 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2022, filed 3 Nov 2022.